DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

Information source: Case Western Reserve University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus

Intervention: Vancomycin (Drug)

Phase: Phase 1

Status: Active, not recruiting

Sponsored by: Case Western Reserve University

Official(s) and/or principal investigator(s):
Elliott C Dasenbrook, MD MHS, Principal Investigator, Affiliation: Case Western Reserve University School of Medicine


The purpose of this study is to determine the pharmacokinetics and safety of inhaled vancomycin in patients with cystic fibrosis.

Clinical Details

Official title: Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Area Under Curve (AUC)

Secondary outcome:

Change in FEV1% Predicted

Change in Patient Symptoms

Change in Sputum Cell Counts

Serum Vancomycin Peak Concentration

Oxygen Saturation

Adverse Events

Maximum Concentration

Time to Peak Concentration

Detailed description: The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection in patients with cystic fibrosis has increased dramatically over the last decade. Epidemiologic evidence suggests that persistent infection with MRSA may result in an increased rate of decline in FEV1 and shortened survival. Treatment of MRSA is a top priority. Inhaled antibiotics offer the advantage of high concentrations of antibiotic at the site of infection (the airway) while minimizing systemic side effects. Vancomycin is a glycopeptide antibiotic that has activity against MRSA. Anecdotal and retrospective peer-reviewed studies have demonstrated that inhaled vancomycin is safe and potentially effective in patients with cystic fibrosis and MRSA airway infection. Data evaluating the pharmacokinetics of vancomycin in sputum are needed before pursuing treatment trials.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Male or female ≥ 18 years of age.

- Confirmed diagnosis of CF based on the following criteria:

- positive sweat chloride > 60 mEq/liter (by pilocarpine iontophoresis) and/or

- a genotype with two identifiable mutations consistent with CF or abnormal NPD,


- one or more clinical features consistent with the CF phenotype.

- Chronic sputum producer able to spontaneously produce sputum

- FEV1 > 40% of predicted normal for age, gender, and height

- Previous use of any inhaled antibiotics within the last year

- Ability to provide written informed consent

- Ability to adhere to the protocol

Exclusion Criteria:

- Use of inhaled or intravenous vancomycin within two weeks of the study visit

- Known history of intolerance to inhaled vancomycin or inhaled albuterol.

- Known history of hypersensitivity to vancomycin or other glycopeptide antibiotics

- History of sputum culture with Burkholderia cepacia complex in the last two years.

- Pregnancy

- Woman who are lactating and not willing to stop nursing on the day of the study visit

and the subsequent 48 hours.

- Current use of oral corticosteroids in doses exceeding the equivalent of 10mg of

prednisone a day or 20mg of prednisone every other day.

- Patients not willing to hold other inhaled antibiotics (for example TOBI, Cayston, or

Colistin) for at least 2 days prior to the study visit.

- Patients not willing to hold loop diuretics (i. e. furosemide, torsemide, ethacrynic

acid) on the morning of the study visit.

- History of ABPA or reactive airways disease that has required treatment within the

last year.

- Creatinine greater than 2. 0 mg/dL within the last year.

- Oxygen saturation ≤ 92% on room air.

- History of patient reported hearing loss

- Any serious or active medical or psychiatric illness, which in the opinion of the

investigator, would interfere with patient treatment, assessment, or adherence to the protocol.

- History of or listed for solid organ or hematological transplantation

Locations and Contacts

Rainbow Babies and Children's Hospital, Univeristy Hospitals Case Medical Center, Cleveland, Ohio 44106, United States
Additional Information

Related publications:

Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010 Jun 16;303(23):2386-92. doi: 10.1001/jama.2010.791.

Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008 Oct 15;178(8):814-21. doi: 10.1164/rccm.200802-327OC. Epub 2008 Jul 31.

Dasenbrook EC. Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Curr Opin Pulm Med. 2011 Nov;17(6):437-41. doi: 10.1097/MCP.0b013e32834b95ed. Review.

Doe SJ, McSorley A, Isalska B, Kearns AM, Bright-Thomas R, Brennan AL, Webb AK, Jones AM. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros. 2010 Mar;9(2):104-9. doi: 10.1016/j.jcf.2009.11.009. Epub 2010 Jan 3.

Starting date: January 2012
Last updated: January 25, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017